WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · HB 216

Legislative bill overview

HB 216 addresses prescription drug regulation in Hawaii, though the specific provisions are not detailed in the available legislative history. The bill was introduced in January 2025 and referred to three committees: Health (HLT), Consumer Protection & Commerce (CPC), and Finance (FIN), indicating it involves healthcare policy with financial and consumer protection implications.

Why is this important

Prescription drug policy directly affects healthcare affordability and access for Hawaii residents. Committee referrals to Finance suggest the bill may involve cost controls, pricing mechanisms, or insurance coverage—issues that impact both individual consumers and the state budget.

Potential points of contention

  • Cost control mechanisms vs. drug industry concerns: Any pricing or reimbursement controls may face opposition from pharmaceutical manufacturers and distributors
  • Insurance coverage mandates: Expanded coverage requirements could increase insurance premiums or state healthcare costs
  • Implementation feasibility: Hawaii's geographic isolation and smaller market may create unique challenges in drug distribution and pricing compared to mainland states

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.